(RTTNews) - Jazz Pharmaceuticals plc (JAZZ), Wednesday announced a global license agreement with Denmark-based Saniona to obtain exclusive worldwide rights to develop SAN2355, a preclinical, selective small molecule activator for epilepsy treatment.
As per the deal, Saniona will receive an upfront payment of $42.5 million, development and regulatory milestone payments of upto $192.5 million, and commercial milestone payments of upto $800 million.
Following the deal, Jazz will lead and fund further development, regulatory submissions, and global commercialization activities regarding SAN2355.
In the pre-market hours, JAZZ is trading at $119.45, up 0.35 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Jazz Pharmaceuticals Enters Into Global License Agreement To Develop SAN2355
Published 2 months ago
Aug 20, 2025 at 12:02 PM
Neutral
Auto